Peyona (previously Nymusa)

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Kaffeina citrate

Available from:

Chiesi Farmaceutici SpA

ATC code:

N06BC01

INN (International Name):

caffeine

Therapeutic group:

Psychoanaleptics,

Therapeutic area:

Apnea

Therapeutic indications:

It-trattament tal-primarja apnea tal-trabi tat-twelid qabel iż-żmien.

Product summary:

Revision: 13

Authorization status:

Awtorizzat

Authorization date:

2009-07-02

Patient Information leaflet

                                21
B. FULJETT TA’
TAGĦRIF
22
FULJETT TA’
TAGĦRIF: INFORMAZZJONI G
ĦALL-UTENT
PEYONA 20 MG/ML SOLUZZJONI
GĦALL-INFUŻJONI U SOLUZZJONI ORALI
caffeine citrate
AQRA SEW DAN IL-FULJETT KOLLU QABEL IL-KURA B’DIN
IL-MEDIĊINA PERESS LI FIH INFORMAZZJONI
IMPORTANTI
GĦAT-
TARBIJA TAT-TWELID
TIEGĦEK
.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib tat-tarbija
tiegħek.
-
Jekk it-tarbija tat-twelid tiegħek ikollha xi effett sekondarju,
kellem lit-tabib tat-tarbija tiegħek.
Dan jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f’dan
il-fuljett. Ara sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Peyona u għalxiex jintuża
2.
X’għandek tkun taf qabel it-tarbija tiegħek tingħata Peyona
3.
Kif għandek tuża Peyona
4.
Effetti sekondarji possibbli
5.
Kif taħżen Peyona
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU PEYONA U
GĦALXIEX
JINTUŻA
Peyona fih is-sustanza attiva caffeine citrate, li huwa stimulant
tas-sistema nervuża ċentrali, u jagħmel
parti minn grupp ta’ mediċini msejħa methylxanthines.
Peyona jintuża fil-kura ta’ interruzzjoni fit-teħid tan-nifs fi
trabi prematuri (apneja primarja ta’ trabi
tat-twelid prematuri).
Dawn il-perijodi qosra meta t-trabi prematuri jieqfu jieħdu n-nifs
iseħħu għax iċ-ċentri tat-teħid tan-
nifs tat-tarbija ma jkunux żviluppaw kompletament.
Din il-mediċina ġie muri li tnaqqas in-numru ta’ episodji ta’
interruzzjoni fin-nifs fi trabi tat-twelid
prematuri.
2.
X’GĦANDEK TKUN TAF QABEL IT-TARBIJA
TIEGĦEK
TINGĦATA PEYONA
TUŻAX PEYONA

Jekk it-tarbija tat-twelid tiegħek hija allerġika għal caffeine
citrate jew għal xi sustanza oħra ta’
din il-mediċina (elenkati fis-sezzjoni 6).
TWISSIJIET U PREKAWZJONIJIET
Kellem lit-tabib tat-tarbija tiegħek qabel it-tarbija tat-twelid
tiegħek tingħata Peyona.
Qabel ma tibda kura għall-apneja tal-prematurita b’Peyona kawżi
oħra ta’ apneja għandhom jiġu
esklużi jew ikkurati kif jixraq mit-tabib tat-
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU
TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT
MEDIĊINALI
Peyona 20 mg/mL soluzzjoni għall-infużjoni u soluzzjoni orali
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull mL fih 20 mg caffeine citrate (ekwivalenti għal 10 mg caffeine).
Kull ampulla ta’ 1 mL fiha 20 mg caffeine citrate (ekwivalenti għal
10 mg caffeine)
Kull ampulla ta’ 3 mL fiha 60 mg caffeine citrate (ekwivalenti għal
30 mg caffeine).
Għal-lista s
ħ
i
ħ
a ta' eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA
FARMAĊEWTIKA
Soluzzjoni għall-infużjoni.
Soluzzjoni orali.
Soluzzjoni milwiema, ċara u bla kulur f’pH=4.7.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET
TERAPEWTIĊI
Kura ta’ apneja primarja fi trabi tat-twelid prematuri.
4.2
POŻOLOĠIJA U METODU TA’ KIF
GĦANDU
JINGĦATA
Kura b’caffeine citrate għandha tinbeda taħt is-superviżjoni
ta’ tabib b’esperjenza fil-kura intensiva ta’
trabi tat-twelid. Il-kura għandha tingħata biss f’taqsima ta’
kura intensiva ta’ trabi tat-twelid fejn
hemm disponibbli faċilitajiet xierqa għas-sorveljanza u
l-monitoraġġ tal-pazjent.
Pożoloġija
Il-kors ta’ dożaġġ rrakkomandat fi trabi li ma kienux ikkurati
minn qabel hija doża għolja tal-bidu ta’
20 mg caffeine citrate kull kg ta’ piz tal-ġisem mogħtija permezz
ta’ infużjoni bil-mod fil-vini fuq
medda ta’ 30 minuta, bl-użu ta’ pompa ta’ l-infużjoni
b’siringa jew strument ieħor għall-infużjoni
mkejla. Wara intervall ta’ 24 siegħa, jistgħu jingħataw dożi
ta’ manteniment ta’ 5 mg kull kg ta’ piz
tal-ġisem permezz ta’ infużjoni bil-mod fil-vini fuq medda ta’
10 minuti kull 24 siegħa. Bħala
alternattiva, dożi ta’ manteniment ta’ 5 mg kull kg ta’ piz
tal-ġisem jistgħu jingħataw permezz ta’
għoti orali, bħal minn ġo tubu nażogastriku, kull 24 siegħa.
Id-doża għolja tal-bidu rrakkomandata u d-dożi ta’ manteniment
ta’ caffeine citrate huma mniżżla fit-
tabella li ġejja li tikklarifika ir-relazzjoni bejn il-volum ta’
l-injezzjoni u d-dożi mogħ
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-12-2021
Public Assessment Report Public Assessment Report Bulgarian 16-09-2020
Patient Information leaflet Patient Information leaflet Spanish 22-12-2021
Public Assessment Report Public Assessment Report Spanish 16-09-2020
Patient Information leaflet Patient Information leaflet Czech 22-12-2021
Public Assessment Report Public Assessment Report Czech 16-09-2020
Patient Information leaflet Patient Information leaflet Danish 22-12-2021
Public Assessment Report Public Assessment Report Danish 16-09-2020
Patient Information leaflet Patient Information leaflet German 22-12-2021
Public Assessment Report Public Assessment Report German 16-09-2020
Patient Information leaflet Patient Information leaflet Estonian 22-12-2021
Public Assessment Report Public Assessment Report Estonian 16-09-2020
Patient Information leaflet Patient Information leaflet Greek 22-12-2021
Public Assessment Report Public Assessment Report Greek 16-09-2020
Patient Information leaflet Patient Information leaflet English 22-12-2021
Public Assessment Report Public Assessment Report English 16-09-2020
Patient Information leaflet Patient Information leaflet French 22-12-2021
Public Assessment Report Public Assessment Report French 16-09-2020
Patient Information leaflet Patient Information leaflet Italian 22-12-2021
Public Assessment Report Public Assessment Report Italian 16-09-2020
Patient Information leaflet Patient Information leaflet Latvian 22-12-2021
Public Assessment Report Public Assessment Report Latvian 16-09-2020
Patient Information leaflet Patient Information leaflet Lithuanian 22-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-12-2021
Public Assessment Report Public Assessment Report Lithuanian 16-09-2020
Patient Information leaflet Patient Information leaflet Hungarian 22-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 22-12-2021
Public Assessment Report Public Assessment Report Hungarian 16-09-2020
Patient Information leaflet Patient Information leaflet Dutch 22-12-2021
Public Assessment Report Public Assessment Report Dutch 16-09-2020
Patient Information leaflet Patient Information leaflet Polish 22-12-2021
Public Assessment Report Public Assessment Report Polish 16-09-2020
Patient Information leaflet Patient Information leaflet Portuguese 22-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 22-12-2021
Public Assessment Report Public Assessment Report Portuguese 16-09-2020
Patient Information leaflet Patient Information leaflet Romanian 22-12-2021
Public Assessment Report Public Assessment Report Romanian 16-09-2020
Patient Information leaflet Patient Information leaflet Slovak 22-12-2021
Public Assessment Report Public Assessment Report Slovak 16-09-2020
Patient Information leaflet Patient Information leaflet Slovenian 22-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 22-12-2021
Public Assessment Report Public Assessment Report Slovenian 16-09-2020
Patient Information leaflet Patient Information leaflet Finnish 22-12-2021
Public Assessment Report Public Assessment Report Finnish 16-09-2020
Patient Information leaflet Patient Information leaflet Swedish 22-12-2021
Public Assessment Report Public Assessment Report Swedish 16-09-2020
Patient Information leaflet Patient Information leaflet Norwegian 22-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 22-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 22-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 22-12-2021
Patient Information leaflet Patient Information leaflet Croatian 22-12-2021
Public Assessment Report Public Assessment Report Croatian 16-09-2020

Search alerts related to this product